First and only BTK inhibitor to demonstrate favourable overall survival trend vs. standard-of-care chemoimmunotherapy in this setting
Augtyro is the only FDA-approved treatment option for NTRK-positive tumors studied in both TKI-naïve and TKI-pretreated patients across solid tumors
There is an urgent need for more therapeutic treatment options for patients with painful osteoarthritis
Jubilant's Radiopharma Business to expand positron emission tomography radiopharmacy network
Over 13 million US adults aged 50-59 years have a medical condition that increases their risk of severe RSV outcomes
Approval based on results from T2NOW, one of the largest paediatric type-2 diabetes Phase III trials to date
Co-founder and previous CEO Lowry Curley becomes Chief Scientific Officer
Sapala has a strong customer base including innovator Pharma, CDMOs & diagnostic companies
SYNERGY-NASH results were presented at the European Association for the Study of the Liver Congress 2024 and simultaneously published in The New England Journal of Medicine
Glenmark's current portfolio consists of 197 products authorized for distribution in the U.S. marketplace
Subscribe To Our Newsletter & Stay Updated
